Alembic Pharmaceuticals receives USFDA tentative approval for Ribociclib Tablets

Ribociclib tablet indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy.
Read The Rest at :